MoonLake Immunotherapeutics (MLTX) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• MoonLake Immunotherapeutics is expected to report Q3 2026 results before market open on November 4, with analysts forecasting a loss of $0.77 per share. The earnings call is scheduled for November 5 at 12:30 p.m. ET.
• MoonLake previously reported a quarterly loss of $0.84 per share, beating consensus estimates of a $0.91 loss. Analysts project losses of $3.34 per share for the current fiscal year and $3.40 for the next.
• Shares opened at $11.93, well below their 52-week high of $23.29, while analyst sentiment is mixed: the stock has an average “Hold” rating and a consensus price target of $28.50. The company’s lead candidate is sonelokimab, an investigational therapy targeting inflammatory diseases.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect MoonLake Immunotherapeutics to announce earnings of ($0.77) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:30 PM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.07. On average, analysts expect MoonLake Immunotherapeutics to post ($3.34) EPS for the current fiscal year and ($3.40) EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Performance

Shares of MoonLake Immunotherapeutics stock opened at $11.93 on Wednesday. MoonLake Immunotherapeutics has a 1 year low of $9.37 and a 1 year high of $23.29. The company has a market capitalization of $1.02 billion, a P/E ratio of -3.11 and a beta of 1.08. The company's fifty day moving average is $12.77 and its two-hundred day moving average is $16.54.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MLTX. Weiss Ratings raised MoonLake Immunotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 21st. Leerink Partners boosted their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an "outperform" rating in a research report on Wednesday, July 1st. Wall Street Zen downgraded MoonLake Immunotherapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday, September 27th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, September 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, October 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of "Hold" and an average target price of $28.50.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company is advancing medicines designed to address conditions in which the immune system contributes to chronic inflammation and tissue damage.

Its lead product candidate is sonelokimab, an investigational Nanobody-based therapy designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.